AAGBI guidelines: the use of blood components and their alternatives 2016
Visit the link below:
AAGBI guidelines: the use of blood components and their alternatives 2016 - Klein - 2016 - Anaesthesia - Wiley Online Library
AAGBI guidelines: the use of blood components and their alternatives 2016 - Klein - 2016 - Anaesthesia - Wiley Online Library
Recommendations
- All patients should have their haemoglobin concentration (Hb) measured before listing for major elective surgery.
- Patients who are anaemic by the World Health Organization definition (Hb men < 130 g.l−1, women < 120 g.l−1) should be investigated before elective surgery and treated appropriately, and elective non-urgent surgery other than caesarean section should be delayed.
- Where blood transfusion is anticipated, this and alternatives to transfusion should be discussed with the patient before surgery, and this should be documented.
- Red blood cells should be transfused one unit at a time, and the patient's Hb should be checked before each unit transfused, unless there is ongoing bleeding or a large deficit that needs correcting.
- The use of intra-operative cell salvage and tranexamic acid administration should be considered in all non-obstetric patients where blood loss > 500 ml is possible and in traumatic and obstetric major haemorrhage.
- Blood components should be prescribed for small children by volume rather than number of units.
- Every institution should have a massive transfusion protocol which is regularly audited and reviewed.
- Group O red cells for transfusion should be readily available in the clinical area, in case haemorrhage is life-threatening. Group-specific red cells should be available within a very short time (15–20 min) of the laboratory receiving correctly-labelled samples and being informed of the emergency requirement for blood.
- During major haemorrhage due to trauma and obstetrics, consideration should be given to transfusing red cells and FFP in preference to other intravenous fluid.
- Patients who continue to actively bleed should be monitored by point-of-care and/or regular laboratory tests for coagulation, fibrinogen and platelet counts or function, and a guide for transfusion should be FFP if INR > 1.5, cryoprecipitate if fibrinogen < 1.5 g.l−1 and platelets if platelet count < 75 × 109.l−1.